Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the BOLT Biotherapeutics Strategic Update Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, we will conduct a question and answer session. Instructions will be given at that time. As a reminder, this call may be recorded. I would like to hand the call over to Willie Quinn, incoming Chief Executive Officer of BOLT Biotherapeutics. Please go ahead, sir. Thank you, and good afternoon, everyone. This afternoon, we issued our first quarter 2024 financial results and business update, which outlines the topics we plan to discuss today. You can access the press release by going to the investors and media section of our website at www.boltbio.com. I am joined today by Randy Schatzman, outgoing chief executive officer, and Edith Perez, outgoing chief medical officer. I am also joined by some newly promoted members of BOLT's senior leadership team, including Michael Alonso, co-founder of BOLT and newly promoted senior vice president of research, and Don Colburn, newly promoted senior vice president of clinical development. Before we begin, I'd like to remind everyone that during this call, we will be making forward-looking statements that are subject to a number of risks and uncertainties. These may cause our actual results to differ materially, and I encourage you to read our SEC filings for more details on these risks and uncertainties. You are cautioned not to place any undue reliance on these forward-looking statements, and BOLT disclaims any obligations to update such statements. To start, I'd like to thank everyone for joining us today. As you all know, we don't normally have earnings calls, but we decided it would be a good idea to have a call today to clearly communicate our new visi...